EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

02.11.18

Pharma Patents Have Become Harder to Enforce, So IAM Together With the Patent Microcosm Sets Up Lobbying Events

Posted in America, Deception, Europe, Patents at 9:31 am by Dr. Roy Schestowitz

IAM: When “alternative facts” are up for sale (if one can afford them)

Battistelli and IAM

Summary: The difficulty associated with enforcing certain types of patents (more so after Mayo and § 101) means that litigious attitudes and reliance on law firms are decreasing; IAM strikes back with another one of its many lobbying events (designed to shape public opinion and influence key decision-makers)

THE concept of patents is pretty much universal, but not all patents are created equal. There are different sorts of patents (“families”) pertaining to or belonging to different domains. Speaking of them all as though they’re the same is the recipe for meaningless debates. Not all patents, for example, are a matter of life or death. Ethical aspects apply in some cases; sometimes pure economics.

“Not all patents, for example, are a matter of life or death.”As we discovered quite recently, EPO oppositions can crash companies. In other words, wrong decisions (or intentions) to grant can be truly harmful and pretty awful to workers. Things get pretty freaky when patents are being claimed on life itself. Forward Pharma lost 30% of its value (or valuation) in just one day at the end of January. This was due to an EPO decision. Yes, some sectors are over-reliant on patents; there’s no question about it. Here’s an example from two days ago: (in the UK)

Shares in Scancell Holdings PLC rose sharply on Friday morning as the company said its Moditope immunotherapy platform is to be granted a European patent.

Scancell shares were up 11% on Friday at 13.54 pence per share.

How good is this European Patent (EP)? Well, there’s lack of certainty under Battistelli, so Scancell Holdings PLC might be the next Forward Pharma (a one-day collapse).

“What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.”Pacific Biosciences is meanwhile attempting to ‘compete’ by causing embargo of its rival, Oxford Nanopore. We wrote about it some days ago and received plenty of comments from people involved in this matter. It’s yet another one of those ITC examples where patent litigation is geared towards embargoes and bankruptcies, not innovation. Here is what the face-saving press release said (striving to justify waste of shareholders’ money, spent on litigation). This campaign of patent litigation by Pacific Biosciences backfired pretty badly. “Pacific Bio down 2% premarket on ITC patent ruling,” Wall Street media stated shortly thereafter. To quote: “The ITC interpreted the term “single-molecule sequencing” as limited to sequencing-by-synthesis approaches, determining that Oxford’s sequencing approach is not “single-molecule sequencing.””

What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.

We have become increasingly supportive of the USPTO because it continues to deny patents on life and even software patents. PTAB helps and gravitates towards that. See the latest PTAB Life Sciences Report by John Cravero and Pharma Patents Blog writing about 35 U.S.C. § 101 rejections (not just based on Alice but also Mayo):

We’ve written previously about ex parte decisions of the Patent Trial and Appeal Board (PTAB) affirming patent eligibility rejections that seem to be inconsistent with the USPTO’s Subject Matter Eligibility Guidance. Apparently, applicants should be wary about appealing any rejection of a diagnostic method claim, because the PTAB may enter sua sponte patent eligibility rejections even if the examiner did not make a § 101 rejection.

Aside from § 101 there’s also 35 U.S.C. § 102. Hospira, based on this blog post, wins again. MedCo’s patent has been declared bogus as per § 102. To quote:

In the litigation, Hospira argued both (1) that the MedCo patents were invalid and (1) that Hospira’s proposed generic Angiomax drug would not infringe. The district court sided with MedCo on the first point (patents not invalid) but with Hospira on the second (patents not infringed). On appeal, the Federal Circuit has affirmed the non-infringement ruling but reversed on the on sale issue. The interesting portion is the on sale question.

Benjamin Anger and Jacob R. Rosenbaum wrote about it some days ago (very detailed).

“They get what they paid for. It’s pure lobbying/marketing.”As one can expect, the litigation ‘industry’ isn’t particularly happy about that. Many patents are being invalidated, which must be causing decrease in demand for patents and lawsuits (their main “offerings” or “services” or “products”).

There’s a “Pharma and Biotech IP Summit” being organised by IAM and as one can expect, the bill for this lobbying event is being footed by the main participants. “Finnegan is a Gold sponsor of IAM Magazine,” it says. There’s therefore a paid-for ‘talk’ (marketing). This not only helps Finnegan control the ‘debate’; it also keeps IAM on their ‘good side’ (maybe IAM will give Finnegan some more of these bogus ‘rewards’ or ‘endorsements’). “Jen Roscetti will present “The View from the United States” at @IAM_magazine’s #Pharma and #Biotech #IP Summit in London,” Finnegan wrote the other day. They get what they paid for. It’s pure lobbying/marketing.

“Either way, “Pharma and Biotech IP Summit” is an IAM sham. It’s sponsored by and dominated by the patent microcosm.”With all honesty, more people ought to speak out about IAM’s “business model”, which involves collecting cash, pushing agenda (in the form of ‘news’ or staged ‘debates’), offering bogus ‘endorsements’, and issuing 'studies' for people like Battistelli (bolstering his lies). There’s nothing benign about it. IAM is effectively a think tank and even some less senior insiders must have realise it. Several of them left, only to be replaced by relatively young and inexperienced writers. Tim Lince, it should be noted, is still listed as a writer at IAM, but he wrote nothing this year and only 1 (one!) blog post last year. Many writers left and perhaps associating with people Battistelli (as we last noted last night) won’t save them but only cause further harm.

Either way, “Pharma and Biotech IP Summit” is an IAM sham. It’s sponsored by and dominated by the patent microcosm. It’s like a propaganda platform facilitated by Joff Wild and his cohorts. He did the same for UPC (with cash from the EPO’s PR firm).

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

What Else is New


  1. Links 17/1/2019: ZFS Debate Returns, AWS Pains Free Software

    Links for the day



  2. US Patent Lawyers Will Need to Change Profession or End up Becoming Abundantly Redundant, Unemployed

    In the age of Patent Trial and Appeal Board (PTAB) inter partes reviews (IPRs) and 35 U.S.C. § 101 it’s too risky to sue with dodgy patents; moreover, the Federal Circuit‘s growing adoption of Alice means that no recent cases have given hope to patent maximalists and litigation frequency has fallen again (at double-digit rates)



  3. Links 16/1/2019: Deepin 15.9 Released and Mozilla Fenix

    Links for the day



  4. Brexit Has Failed, But So Has the Unitary Patent (UPC)

    Even though all signs indicate that the Unified Patent Court (UPC) will never become a reality spin is to be expected from Team UPC, still looking to profit from more litigation and expanded scope



  5. IBM, Which Will Soon be Buying Red Hat, is Promoting Software Patents in Europe

    Even days apart/within confirmation of IBM's takeover of Red Hat IBM makes it clear that it's very strongly in favour of software patents, not only in the US but also in Europe



  6. Team UPC on Dead UPC: Choosing Gowns for Corpses

    The campaign of lies, long waged by Team UPC in order to manipulate politicians and courts, hasn’t stopped even in 2019 (IAM threw in the towel, but some of Team UPC is still ‘embalming’ UPCA)



  7. Links 15/1/2019: MX Linux MX-18 Continuum Reviewed, Mageia 7 Artwork Voting

    Links for the day



  8. Council of Europe (CoE) Recognises There's No Justice at the EPO

    It’s now the Council of Europe‘s turn to speak out about the grave state of international organisations that exist in Europe but aren’t subjected to European law (which they routinely violate with impunity)



  9. Dominion Harbor -- Armed by Microsoft's Biggest Patent Troll -- Goes After the World's Biggest Android OEMs, Huawei and Samsung

    Dominion Harbor, the patent troll that gets bucketloads of patents from Intellectual Ventures (a patent troll strongly connected to Microsoft and Bill Gates), is still suing using shell entities



  10. Links 14/1/2019: Linux 5.0 RC2 and DXVK 0.95 Released

    Links for the day



  11. Only the Higher Courts -- Not Trump's 'Poster Child' -- Can Bring Back Software Patents

    Software patents are not making a "comeback" as some like to claim; in fact, the latest court cases and notably their outcomes suggest that nothing has changed



  12. “Uniloc is a Lawsuit Factory”

    Apple is a very secretive company, so it is hard to know what goes on with the patent troll Uniloc



  13. European Patent Office a Textbook Example of Lawless, Rogue Institutions

    The tyrannical nature of the EPO is still being demonstrated by the sad fate of Patrick Corcoran; technical judges at the EPO are feeling intimidated by nontechnical politicians and bankers



  14. No, Software Patents Are Not Poised to Make a Comeback Under New US Patent Office Rules

    Poor understanding of the difference between patent courts and patent offices is to blame for widely-spread misinformation from Ars Technica (part of Condé Nast)



  15. IP Kat Has Turned From EPO Critic (to the Point of Being Blocked by the EPO) to EPO Whitewasher That Gags EPO Whistleblowers

    The EPO tried to forcibly gag (block) IP Kat like it blocks Techrights (since 2014); failing that, the EPO got the blog to just act as a whitewashing operation for Team Campinos (more or less the same as Team Battistelli)



  16. Linspire 'Reborn' is Still Working for Microsoft and Facilitating Surveillance on GNU/Linux Users

    GNU/Linux spyware scandals may be back (and it's not about Canonical and Amazon but Linspire and Microsoft); Microsoft is meanwhile exposing innocent kids to pedophiles and it refuses to explain or defend this



  17. Links 12/1/2019: Wine 4.0 RC6, X-Plane 11.30, SuperTuxKart 0.10 Beta, LibreOffice 6.2 RC2

    Links for the day



  18. The EPO's Low Patent Quality Can Kill the European Software Industry and Kill People Too

    The patents granted by the EPO are often invalid as per courts' decisions, which means that fake/illegitimate European Patents saturate the market and discourage development (e.g. of software and life-saving drugs)



  19. The Fiction That Spain (or Italy) Can Salvage the UPC

    The proponents/lobbyists of the Unified Patent Court (UPC), firms that make money from patent litigation (we collectively call these "Team UPC"), are nowadays backpedaling, having come to grips with the death of the UPC, realising it's time to save face by pretending everything they said in the past wasn't a lie



  20. Links 11/1/2019: IBM-Red Hat Obstacle Cleared, Toyota Chooses Linux

    Links for the day



  21. EPO President “Campinos is Wasting His Credibility With “Sweet” Communiqués Full of Hot Air and Storytelling”

    EPO insiders insist if not demand that all those responsible for the corruption and the abuses be removed; Campinos has done the opposite by promoting those who caused harm and turning his overseer into his subordinate



  22. The Emptiness of the Linux Foundation's Commitment to Linux and Its True Openness... to Corporate Cash (in Exchange for Influence)

    Like Pence and Moreno, who exchange a political refugee for loans, the Linux Foundation abandons its commitment to GNU/Linux in exchange for maximisation of financial contributions



  23. Links 10/1/2019: Linux 4.20.1, GNOME 3.31.4 Released

    Links for the day



  24. Links 9/1/2019: Qubes OS 4.0.1, Bash 5.0

    Links for the day



  25. European Patent Office Saga in 2019: “95% of the People Responsible for the Misery Are Still in Place and Have Not Even Been Rebuked”

    No signs of reformation at Europe's second-largest institution, which still suffers from justice deficit and blatant corruption



  26. Links 8/1/2019: Godot 3.1 Reaches Beta, Tidelift Gets Money

    Links for the day



  27. EPO Corruption is Helping Patent Maximalists in the United States

    The law firms that promote abstract patents in the United States (in the face of growing opposition from courts) adopt the EPO as a sort of 'poster child' because quality of European Patents keeps decreasing and lawlessness is increasing



  28. Links 7/1/2019: Linux 5.0 RC1

    Links for the day



  29. Words to Avoid: Cloud, Serverless, Microservices and More

    The marketing industry is hijacking press coverage and journalism has turned into a laughable mash-up of buzzwords; technical people ought to push back



  30. One Week After Site Migration

    January 1st marked an important milestone/accomplishment: managing to fully migrate Techrights to the new environment (datacentre) with zero downtime, just in time for the new year


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts